Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. Hutchings M, et al. Among authors: ferlini c. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19. J Clin Oncol. 2021. PMID: 33739857 Free PMC article. Clinical Trial.
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G, Haegel H, Schneider A, Giusti AM, Marrer-Berger E, Boetsch C, Walz AC, Pulko V, Sam J, Challier J, Ferlini C, Odermatt A, Umaña P, Bacac M, Klein C. Leclercq G, et al. Among authors: ferlini c. J Immunother Cancer. 2021 Jul;9(7):e002582. doi: 10.1136/jitc-2021-002582. J Immunother Cancer. 2021. PMID: 34326166 Free PMC article.
RON and cisplatin resistance in ovarian cancer cell lines.
Prislei S, Mariani M, Raspaglio G, Mozzetti S, Filippetti F, Ferrandina G, Scambia G, Ferlini C. Prislei S, et al. Among authors: ferlini c. Oncol Res. 2010;19(1):13-22. doi: 10.3727/096504010x12828372551713. Oncol Res. 2010. PMID: 21141737
Novel drugs targeting microtubules: the role of epothilones.
Ferrandina G, Mariani M, Andreoli M, Shahabi S, Scambia G, Ferlini C. Ferrandina G, et al. Among authors: ferlini c. Curr Pharm Des. 2012;18(19):2793-803. doi: 10.2174/138161212800626238. Curr Pharm Des. 2012. PMID: 22390763 Review.
Molecular mechanisms of patupilone resistance.
Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, Bartollino S, Gallo D, Scambia G, Ferlini C. Mozzetti S, et al. Among authors: ferlini c. Cancer Res. 2008 Dec 15;68(24):10197-204. doi: 10.1158/0008-5472.CAN-08-2091. Cancer Res. 2008. PMID: 19074887
116 results